Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

106.63
+0.25000.24%
Volume:3.88M
Turnover:415.17M
Market Cap:132.93B
PE:280.61
High:107.56
Open:106.11
Low:105.91
Close:106.38
Loading ...

Gilead Sciences' (NASDAQ:GILD) Conservative Accounting Might Explain Soft Earnings

Simply Wall St.
·
07 Mar

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

Zacks
·
07 Mar

Big Pharma wants to bring back a tax break that could save it $15 billion

Quartz
·
07 Mar

BUZZ-Status of Vertex's painkiller on UnitedHealth lists poses modest challenge, BMO says

Reuters
·
07 Mar

5 Big Biopharmaceutical Stocks That Are Finding Favor -- Barrons.com

Dow Jones
·
06 Mar

Gilead Sciences Is Maintained at Buy by B of A Securities

Dow Jones
·
06 Mar

BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating

MT Newswires Live
·
05 Mar

Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

Zacks
·
05 Mar

Bank of America Securities Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
05 Mar

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Zacks
·
05 Mar

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

Simply Wall St.
·
05 Mar

Gilead Sciences Is Maintained at Outperform by Oppenheimer

Dow Jones
·
04 Mar

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS
·
04 Mar

Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating

MT Newswires Live
·
04 Mar

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Zacks
·
04 Mar

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
04 Mar

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Zacks
·
04 Mar

Gilead Sciences sets aside $200 million to resolve HIV drug probe

Reuters
·
04 Mar

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Zacks
·
03 Mar

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Zacks
·
03 Mar